QTTB Nasdaq Pharmaceutical Preparations Financials FY2017βFY2025
Q32 Bio Inc. had $53.7M of revenue in fiscal 2025. Over five years, revenue changed +81.9% a year on average.
Last close Β· Oct 23, 2026
$8.65
1.7%Hi! I read Q32 Bio Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Does it make a profit?
55.5%
Yes. It keeps 55.5% of every sale as profit.
Does profit turn into cash?
β62.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
2.8x
One share costs 2.8 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Q32 Bio Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 17 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 5, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 5, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Mar 10, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 13, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 6, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 8, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Mar 11, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 7, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Q32 Bio Inc. had $53.7M of revenue in fiscal 2025. Over five years, revenue changed +81.9% a year on average. Its operating margin was 31.5%: of every 100 in sales, about 31 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Q32 Bio Inc. made $29.8M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$33.5M in fiscal 2025, β62.4% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Q32 Bio Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $156M | $175M | $25.6M | $78.0M | $48.3M |
| Interest coverage | β | β | β32.2x | β | β |
| Current ratio | 11.1x | 8.0x | 2.0x | 5.0x | 4.9x |
| Quick ratio | 11.1x | 8.0x | 2.0x | 5.0x | 4.9x |
| Total assets | $212M | $228M | $47.1M | $92.3M | $61.8M |
| Total liabilities | $42.1M | $50.5M | $119M | $86.7M | $19.8M |
| Shareholders' equity | $170M | β$131M | β$183M | $5.7M | $42.0M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Q32 Bio Inc. passes 3 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | 2 / 7 | 2 / 7 | 3 / 7 | 1 / 7 | 2 / 7 | 3 / 7 | 3 / 7 |
| Accruals ratio | β26.5% | β6.6% | β4.4% | β12.0% | 5.9% | 49.4% | β25.5% | 28.7% | 82.2% |
| Altman Z'' | 2.40 | 5.57 | 6.11 | 0.56 | 0.07 | β8.21 | β19.44 | β8.39 | β2.11 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | β | $3.7M | $1.7M | $2.7M | $34.0M | $3.2M | β$6.7M | $0.0M | $53.7M |
| Net interest income | β | β | β | β | β | β | $0.7M | $2.8M | $1.1M |
| Research and development | $21.4M | $47.9M | $89.4M | $100M | $93.1M | $98.4M | $31.7M | $48.1M | $19.2M |
| Operating income | β$29.7M | β$59.9M | β$110M | β$130M | β$95.9M | β$133M | β$48.3M | β$66.1M | $16.9M |
| Interest expense | β | β | β | β | β | β | $1.5M | β | β |
| Pretax income | β | β | β | β | β$95.8M | $1.2M | β$87.1M | β$46.1M | $29.8M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.7M | $0.3M | $0.0M | $0.0M |
| Net income | β$30.0M | β$55.6M | β$104M | β$129M | β$95.8M | β$5.0M | β$53.7M | β$47.7M | $29.8M |
| Net income to common | β | β | β | β | β | β | β$0.1M | β$0.0M | $0.0M |
| Diluted EPS | β$12.10 | β$1.95 | β$2.47 | β$2.80 | β$1.73 | β$0.09 | β$153.96 | β$6.58 | $2.42 |
| Diluted shares | 0.00B | 0.03B | 0.04B | 0.05B | 0.06B | 0.06B | 0.00B | 0.01B | 0.01B |
| Cash flow | |||||||||
| Cash from operations | $6.5M | β$42.6M | β$91.4M | β$94.3M | β$110M | β$114M | β$18.7M | β$67.7M | β$33.5M |
| Capital expenditure | $2.0M | $24.9M | $21.8M | $3.7M | $2.4M | $1.3M | $0.0M | $0.1M | $0.0M |
| Free cash flow | $4.5M | β$67.5M | β$113M | β$98.1M | β$112M | β$115M | β$18.7M | β$67.8M | β$33.5M |
| Depreciation and amortization | $0.7M | $1.3M | $6.3M | $8.0M | $8.4M | $1.3M | $0.5M | $0.5M | $0.4M |
| Stock-based compensation | $0.3M | $2.6M | $7.6M | $13.2M | $17.2M | $13.1M | $1.4M | $4.4M | $5.3M |
| Balance sheet | |||||||||
| Cash and short-term investments | $130M | $215M | $262M | $217M | $156M | $175M | $25.6M | $78.0M | $48.3M |
| Current assets | $132M | $222M | $267M | $220M | $192M | $181M | $28.7M | $81.9M | $55.1M |
| Current liabilities | $8.9M | $22.5M | $12.4M | $22.7M | $17.2M | $22.6M | $14.1M | $16.5M | $11.3M |
| Property and equipment, net | $3.2M | $35.6M | $42.7M | $37.0M | $2.3M | $1.1M | $1.8M | $1.4M | $1.0M |
| Total assets | $138M | $259M | $311M | $264M | $212M | $228M | $47.1M | $92.3M | $61.8M |
| Total liabilities | $39.2M | $62.7M | $52.1M | $67.7M | $42.1M | $50.5M | $119M | $86.7M | $19.8M |
| Preferred stock | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$39.5M | $196M | $259M | $196M | $170M | β$131M | β$183M | $5.7M | $42.0M |
| Margins | |||||||||
| Operating margin | β | β1,626.7% | β6,599.2% | β4,821.0% | β282.4% | β4,154.6% | 725.5% | β | 31.5% |
| EBITDA margin | β | β1,591.7% | β6,220.0% | β4,526.2% | β257.9% | β4,114.3% | 718.0% | β | 32.2% |
| Net margin | β | β1,508.6% | β6,237.5% | β4,762.9% | β281.9% | β156.0% | 808.0% | β | 55.5% |
| FCF margin | β | β1,832.3% | β6,794.2% | β3,629.3% | β330.1% | β3,583.1% | 280.9% | β | β62.4% |
| Net interest share of revenue | β | β | β | β | β | β | β10.4% | β | 2.0% |
| Returns | |||||||||
| Return on capital employed | β23.0% | β25.3% | β36.9% | β54.0% | β49.3% | β64.7% | β146.5% | β87.1% | 33.5% |
| Return on equity | β | β70.8% | β45.7% | β56.6% | β52.4% | β25.7% | β | β | 125.1% |
| Return on assets | β21.8% | β28.0% | β36.5% | β44.8% | β40.3% | β2.3% | β39.0% | β68.5% | 38.7% |
| Return on tangible equity | β | β28.3% | β40.2% | β65.7% | β56.4% | β | β | β0.8% | 0.1% |
| Growth | |||||||||
| Revenue growth | β | β | β54.8% | 62.2% | 1,157.3% | β90.6% | β307.3% | β | β |
| FCF growth | β | β1,593.1% | β | β | β | β | β | β | β |
| Share count change | β | 1,051.6% | 47.5% | 9.0% | 20.4% | 3.8% | β99.4% | 2,666.5% | 27.5% |
| Financial health | |||||||||
| Interest coverage | β | β | β | β | β | β | β32.2x | β | β |
| Current ratio | 14.9x | 9.8x | 21.5x | 9.7x | 11.1x | 8.0x | 2.0x | 5.0x | 4.9x |
| Quick ratio | 14.9x | 9.8x | 21.5x | 9.7x | 11.1x | 8.0x | 2.0x | 5.0x | 4.9x |
| Capital allocation | |||||||||
| Capex / revenue | β | 677.0% | 1,310.5% | 138.2% | 7.1% | 40.1% | β0.1% | β | 0.0% |
| Stock comp / revenue | β | 71.2% | 458.3% | 490.3% | 50.8% | 406.9% | β21.5% | β | 9.8% |
| Quality scores | |||||||||
| Piotroski F-score | β | β | 2.0 | 2.0 | 3.0 | 1.0 | 2.0 | 3.0 | 3.0 |
| Altman Z'' | 2.4 | 5.6 | 6.1 | 0.6 | 0.1 | β8.2 | β19.4 | β8.4 | β2.1 |
| Accruals ratio | β26.5% | β6.6% | β4.4% | β12.0% | 5.9% | 49.4% | β25.5% | 28.7% | 82.2% |
Source: SEC EDGAR XBRL filings (CIK 0001661998). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
